Asia’s pharmaceutical industry is at a transformative stage, embracing technology, collaboration, and data-driven strategies to accelerate drug development. Reshaping the Clinical Trial Model has become essential for ensuring faster approvals, patient-centric approaches, and regulatory compliance across emerging Asian markets. As companies adapt to new digital ecosystems, Reshaping the Clinical Trial Model enables pharma leaders to harness AI, remote monitoring, and real-world evidence for more efficient and transparent outcomes. This evolution not only improves patient engagement but also strengthens Asia’s position as a global hub for clinical research excellence.  Read the Full Article